title: Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome.
abstract: Sugar chain binding antibodies have gained substantial attention as biomarkers due to their crucial roles in various disorders. In this study, we developed simple and quick detection method of anti-sugar chain antibodies in sera using our previously developed sugar chain-immobilized fluorescent nanoparticles (SFNPs) for the point-of-care diagnostics. Sugar chain structure on SFNPs was modified with the sugar moieties of the GM1 ganglioside via our original linker molecule to detect anti-GM1 antibodies. The structures and densities of the sugar moieties immobilized on the nanoparticles were evaluated in detail using lectins and sera containing anti-GM1 antibodies from patients with Guillain-Barré syndrome, a neurological disorder, as an example of disease involving anti-sugar chain antibodies. When optimized SFNPs were added to sera from patients with Guillain-Barré syndrome, fluorescent aggregates were able to visually detect under UV light in three hours. The sensitivity of the detection method was equivalent to that of the current ELISA method used for the diagnosis of Guillain-Barré syndrome. These results suggest that our method using SFNPs is suitable for the point-of-care diagnostics of diseases involving anti-sugar chain antibodies.
authors.affiliation: Department of Chemistry, Biotechnology and Chemical Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shinchi
authors.affiliation: Department of Neurology, Dokkyo Medical University, Tochigi 321-0293, Japan; Brain & Mind Research Institute, University of Sydney, Level 7, Building F, 94 Mallett Street, Camperdown, NSW 2050, Australia.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yuki
authors.affiliation: Department of Applied Bioorganic Chemistry, Gifu University, Gifu 501-1193, Japan.
authors.forename: Hideharu
authors.initials: H
authors.lastname: Ishida
authors.affiliation: Department of Neurology, Dokkyo Medical University, Tochigi 321-0293, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Hirata
authors.affiliation: Department of Chemistry, Biotechnology and Chemical Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Wakao
authors.affiliation: Department of Chemistry, Biotechnology and Chemical Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan; SUDx-Biotec Corporation, 1-42-1 Shiroyama, Kagoshima 890-0013, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Suda
mesh_terms: D055910:Antibodies, Immobilized / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D002241:Carbohydrates / Q000276:immunology*; D005455:Fluorescent Antibody Technique / Q000379:methods; D005677:G(M1) Ganglioside / Q000276:immunology; D020275:Guillain-Barre Syndrome / Q000175:diagnosis* / Q000276:immunology*; D006801:Humans; D037102:Lectins / Q000276:immunology; D053758:Nanoparticles / Q000008:administration & dosage*; D019095:Point-of-Care Systems
chemical_list: D055910:Antibodies, Immobilized; D001323:Autoantibodies; D002241:Carbohydrates; D037102:Lectins; D005677:G(M1) Ganglioside